Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)

NCT01781117 is registered in ClinicalTrials.gov with KYU-SUNG LEE as lead sponsor.

NCT NCT01781117
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01781117 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)
Lead sponsor
KYU-SUNG LEE
Phase
Not applicable
Overall status
Completed
Start date
February 28, 2013
Completion date
January 31, 2017
Enrollment
184 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

benign prostatic hypertrophy with outflow obstruction, overactive detrusor